01 / 06
Does 23andMe Test for BRCA?
Yes. The 23andMe BRCA1/BRCA2 (Selected Variants) Genetic Health Risk report is the first and only FDA-authorized direct-to-consumer BRCA test. The report checks 44 selected variants (expanded from the original 3 in August 2023) using genotyping, not gene sequencing.
The FDA originally authorized a three-variant report on March 6, 2018, through the De Novo classification pathway (DEN170046, Class II). That made it the first direct-to-consumer genetic test ever authorized by the FDA for cancer risk. The report stayed at three variants for five years. In August 2023, a new clearance (K223597) under a Predetermined Change Control Plan added 41 more variants in a single update, bringing the total to 44. [1,2,3]
The Predetermined Change Control Plan is significant beyond the variant count: it lets 23andMe add future validated variants without filing a new premarket submission each time, meaning the scope of this test can expand again. [1]
If family history or a known familial variant is driving the decision, the starting point is different. Review who should get a clinically indicated BRCA test before choosing a consumer product.
02 / 06
Which Variants Does It Cover, and for Whom?
The 23andMe BRCA report originally tested three founder mutations found at a rate of about 1 in 40 among people of Ashkenazi Jewish descent. The 2023 expansion added 41 variants aimed at populations the original test barely reached. Still, 44 remains a small fraction of all known pathogenic BRCA changes.
The original three variants
The 2018 report was built around three mutations that cluster in Ashkenazi Jewish populations due to a founder effect:
BRCA1:
185delAG (c.68_69delAG) and 5382insC (c.5266dupC)
BRCA2:
6174delT (c.5946delT)
The approximately 1-in-40 carrier rate among people of Ashkenazi Jewish descent is roughly ten times higher than in the general population. That frequency reflects the founder effect; it does not mean BRCA risk is confined to any single ancestry. People of any background can carry pathogenic BRCA variants, and most of those variants fall outside this three-mutation set. [2,6]
How many BRCA variants are known?
Published sources cite different totals depending on which database they reference, which variant classifications they include, and when they last updated. Rather than collapse these into a single falsely precise number, we report three commonly cited figures with attribution: [2,3,5]
- 4,000+ per 23andMe's own product page [2]
- 3,500+ per genetic counselor Rachel Brandt, via Breastcancer.org [3]
- 5,400+ per FORCE (Facing Our Risk of Cancer Empowered) [5]
These are not interchangeable denominators. The discrepancies reflect different classification criteria and database coverage, not a disagreement about biology. Under any of these counts, 44 is a small percentage.
Coverage differs by ancestry
A fixed 44-variant list captures different shares of known pathogenic variants in different populations. The same negative result therefore does not carry the same residual uncertainty for everyone.
The 23andMe BRCA report's published detection rates vary by ancestry group. These are the company's own figures, not third-party benchmarks: [2]
| Population | Estimated Detection Rate | What This Means in Practice |
|---|---|---|
| Ashkenazi Jewish descent | More than 90% | The three founder variants alone account for the majority of known carriers here. Coverage was strong before the expansion and remains the highest of any group. |
| Black, European, Hispanic/Latino | About 30–40% | Most pathogenic variants in these populations remain outside the 44-variant list. A negative result carries substantial residual uncertainty. |
| East Asian | About 5–25% | The broad range signals uncertainty in the estimate itself. For most people of East Asian descent, a negative result from this test is minimally informative. |
| South Asian | Up to about 35% | “Up to” is a ceiling, not a guarantee. Individual coverage within this category may be considerably lower. |
These are population-level estimates, not individual probabilities. Population labels are broad, ancestry can be mixed, and a person's clinical testing need depends on family and personal history as well as ancestry. [2]
03 / 06
What Does a 23andMe BRCA Result Mean, and What Doesn't It Rule Out?
The 23andMe BRCA report returns one of two outcomes. A “variant detected” result signals increased risk for certain cancers and requires clinical confirmation before any medical decision. A “no variants detected” result means none of the 44 tested variants were found; it does not rule out BRCA risk.
Variant Detected
A finding to confirm, not a diagnosis
The selected variant is associated with increased risk for certain cancers. It must be confirmed with a clinical genetic test before any screening, surgical, reproductive, or treatment decision. Consumer genotyping is not diagnostic-grade sequencing.
No Variant Detected
Not the same as “no risk”
It means none of the 44 selected variants was found. It does not assess the thousands of other reported BRCA1/2 variants, does not evaluate other cancer-risk genes, and does not describe overall cancer risk. A clean result on a 44-variant screen is not a clean bill of genetic health.
These limitations are not fine print. They are FDA requirements built into the authorization. The FDA mandates that 23andMe disclose the following: [1,2]
- Confirmatory testing is required before any medical decision.
- The report is not a substitute for visits with a healthcare professional.
- It does not describe a person's overall risk of cancer.
Genetic counseling is not included with the consumer report.
04 / 06
Frequently Asked Questions
Q1Does 23andMe test for BRCA?
Yes. The 23andMe BRCA1/BRCA2 (Selected Variants) Genetic Health Risk report is the first and only FDA-authorized direct-to-consumer BRCA test. The report currently checks 44 selected variants, expanded from 3 following an FDA clearance in August 2023 (K223597).
Q2Is 23andMe's BRCA test FDA-approved?
It is FDA-authorized, not FDA-approved. That is a meaningful regulatory distinction. The test received De Novo classification (Class II) on March 6, 2018 under decision DEN170046. “FDA-approved” refers to a different premarket pathway (typically PMA or NDA). Both are legitimate, but they are not interchangeable terms.
Q3Can a negative 23andMe result rule out BRCA risk?
No. A negative result means the test did not find any of its 44 selected variants. It does not assess the thousands of other known pathogenic BRCA1/2 changes it does not check. A negative consumer result should not end a conversation with a genetic counselor. It should start one, if your personal or family history suggests elevated risk.
Q4Is whole-genome sequencing more accurate than 23andMe for BRCA?
WGS reads the entire genome rather than checking a fixed variant list. The 23andMe BRCA report covers 44 selected positions with FDA-audited accuracy (>99% concordance to Sanger sequencing) for those specific variants. HLI's $599 WGS service covers the full BRCA1 and BRCA2 genes as part of a genome-wide assessment across 6.4 billion base pairs. The key difference is scope: 44 positions vs. the entire genome.
Q5What is the difference between genotyping and sequencing for BRCA?
Genotyping checks a fixed list of known variant positions on a microarray chip. Sequencing reads the nucleotide-by-nucleotide order of an entire gene or genome. The 23andMe BRCA report uses genotyping (44 positions). A clinical hereditary cancer panel sequences the full BRCA1 and BRCA2 genes. HLI's service sequences the entire genome at approximately 30× coverage. Genotyping is faster and less expensive; sequencing detects novel or rare variants that no fixed list includes.
05 / 06
Why This Beats the Alternatives (and Where It Doesn't)
The 23andMe BRCA report checks 44 variants for $199 with no counseling. A clinical panel sequences BRCA1/2 comprehensively for about $249 self-pay ($0 when ACA preventive criteria apply). HLI's $599 whole-genome sequencing service reads all 6.4 billion base pairs, covering BRCA1/2 alongside cancer, cardiovascular, pharmacogenomic, and metabolic findings in a single report.
These three products answer different questions. Comparing them requires looking at scope, validation, counseling, and follow-up, not only volume of DNA collected.
The three-way comparison
The following table compares the 23andMe BRCA report, a clinical hereditary cancer panel, and HLI whole-genome sequencing across six attributes: cost, BRCA scope, additional coverage, regulatory status, counseling, and best fit.
| Feature | 23andMe BRCA Report | Clinical Hereditary Cancer Panel | HLI Whole-Genome Sequencing |
|---|---|---|---|
| Listed cost | 23andMe BRCA Report$199 (verify current price; 23andMe restructured in 2025) | Clinical Hereditary Cancer PanelAbout $249 self-pay from major labs such as Invitae, Color, and Ambry ($0 out of pocket when ACA preventive criteria and insurance apply) | HLI Whole-Genome Sequencing$599 |
| BRCA scope | 23andMe BRCA ReportFixed list of 44 selected variants (genotyping, not sequencing) | Clinical Hereditary Cancer PanelFull sequencing and deletion/duplication analysis of BRCA1/2; exact scope and validated variant classes vary by lab | HLI Whole-Genome SequencingThe cancer report includes BRCA1 and BRCA2; specific variants and validated variant classes are not published |
| Beyond BRCA | 23andMe BRCA ReportOther consumer health reports vary by product tier | Clinical Hereditary Cancer PanelTypically includes other hereditary cancer genes on the same panel | HLI Whole-Genome SequencingGenome-wide data: cancer, cardiovascular, pharmacogenomic (200+ medications), longevity, and metabolic findings |
| Regulatory / validation | 23andMe BRCA ReportFDA-authorized (De Novo, Class II) for its selected variants; original submission reported >99% concordance to Sanger sequencing | Clinical Hereditary Cancer PanelPerformed in CLIA-certified clinical labs; methods, confirmation protocols, and analytic performance vary by lab | HLI Whole-Genome SequencingCLIA-certified laboratory; 30× whole-genome coverage across coding and non-coding regions |
| Counseling | 23andMe BRCA ReportNot included | Clinical Hereditary Cancer PanelTypically ordered after pre-test counseling, with post-test clinical follow-up | HLI Whole-Genome SequencingNot a replacement for a genetic counselor or clinical confirmation of findings |
| Best fit | 23andMe BRCA ReportLow-cost consumer screening when no specific family variant is known and clinical criteria are not met | Clinical Hereditary Cancer PanelA focused clinical question about hereditary cancer risk, especially with known family history | HLI Whole-Genome SequencingA broader inherited-health picture from a single genome dataset, when the goal extends beyond any one gene |
Prices, report scope, and laboratory practices change. Confirm current details directly with each provider before ordering. For a broader discussion of costs, coverage, and privacy, see BRCA testing costs, insurance, and privacy.
What whole-genome sequencing adds
HLI's $599 service uses approximately 30× whole-genome sequencing across all 6.4 billion base pairs and includes a cancer risk assessment stated to cover BRCA1 and BRCA2, among other genes. That arrives alongside cardiovascular risk scores, pharmacogenomic insights for 200+ medications, and longevity and metabolic traits, all from a single saliva kit.
In product scope, that is a categorically different offering from a 44-variant consumer check. One purchase delivers a genome-wide dataset that can inform decisions across cancer, cardiac health, medication metabolism, and more. A consumer genotyping test delivers a single binary answer on each of 44 positions.
A positive BRCA finding from either pathway (the 23andMe BRCA report or WGS) still needs clinical confirmation before you act on it. A negative result from either should not overrule personal or family history that points toward elevated risk. The difference is in what surrounds the BRCA answer. The 23andMe BRCA report gives you 44 variants. WGS gives you a genome-wide dataset covering BRCA and thousands of other genes, with results across cancer, cardiac, pharmacogenomic, and metabolic health, from one purchase.
Full BRCA coverage. Plus 20,000 genes.
$599 · One saliva kit · AI-powered app.
Explore the $599 WGS Service →06 / 06
Sources and Review Notes
Regulatory and product facts were checked against primary sources on September 28, 2026. The 44-variant count, pricing, service scope, and regulatory status should be rechecked at least every six months. This is a topic where even reputable organizations get the core numbers wrong. Medical review remains pending for this preview.
- 01U.S. Food and Drug Administration. De Novo classification request for the 23andMe Personal Genome Service Pharmacogenetic Reports, Genetic Health Risk Reports, and Carrier Status Reports. DEN170046; authorized March 6, 2018. ↗
- 0223andMe. BRCA1/BRCA2 (Selected Variants) Genetic Health Risk report. Current product scope, detection rate estimates, and FDA-required limitations; accessed September 24, 2026. ↗
- 03Breastcancer.org. Coverage of the expanded 23andMe BRCA report, November 2024. Cited for the 2023 expansion timeline and the 3,500+ known-variant denominator attributed to genetic counselor Rachel Brandt. ↗
- 04Genetic Support Foundation. Genetic-counseling analysis of 23andMe BRCA testing, January 2024. ↗
- 05FORCE: Facing Our Risk of Cancer Empowered. Hereditary cancer and BRCA information. Cited for the 5,400+ known-variant denominator. ↗
- 06National Cancer Institute. BRCA Gene Changes: Cancer Risk and Genetic Testing. ↗